Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Vomiting 2Uterine Cervical Neoplasms 2Nausea 2Condylomata Acuminata 2Breast Neoplasms 2Sezary Syndrome 1Renal Insufficiency 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Kidney Failure, Chronic 1

Interventions

Dexamethasone 22Ondansetron 20Aprepitant 20Palonosetron 17Granisetron 11Calcium Dobesilate 8Therapeutics 7Olanzapine 6dexamethasone acetate 5Doxorubicin 5Cyclophosphamide 5casopitant 4Acupressure 4netupitant 3dolasetron 3Yoga 3Vincristine 3Radiotherapy 3Dronabinol 3Analgesia 3ginger extract 2fosaprepitant 2dexamethasone 21-phosphate 2Tropisetron 2Surveys and Questionnaires 2Psychiatric Rehabilitation 2Prochlorperazine 2Metoclopramide 2Mesna 2Ifosfamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Nausea × Duration of Therapy × Clear all
NCT00092183 2017-05-05

An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)

Merck Sharp & Dohme LLC

Phase 4 Completed
866 enrolled
Breast

Breast Neoplasms, Nausea, Vomiting

NCT00092196 2017-05-05

Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 3 Completed
820 enrolled
Breast

Breast Neoplasms, Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡